BR112014001083B8 - Composto, processo para a preparação de um composto, composição farmacêutica, uso da composiçâo farmacêutica e uso do composto - Google Patents
Composto, processo para a preparação de um composto, composição farmacêutica, uso da composiçâo farmacêutica e uso do compostoInfo
- Publication number
- BR112014001083B8 BR112014001083B8 BR112014001083A BR112014001083A BR112014001083B8 BR 112014001083 B8 BR112014001083 B8 BR 112014001083B8 BR 112014001083 A BR112014001083 A BR 112014001083A BR 112014001083 A BR112014001083 A BR 112014001083A BR 112014001083 B8 BR112014001083 B8 BR 112014001083B8
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- pharmaceutical composition
- preparing
- formula
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Abstract
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN3203CH2011 | 2011-09-19 | ||
IN3203/CHE/2011 | 2011-09-19 | ||
PCT/IN2012/000011 WO2013042135A1 (en) | 2011-09-19 | 2012-01-05 | Heteroaryl compounds as 5-ht4 receptor ligands |
Publications (4)
Publication Number | Publication Date |
---|---|
BR112014001083A2 BR112014001083A2 (pt) | 2019-10-01 |
BR112014001083A8 BR112014001083A8 (pt) | 2021-08-24 |
BR112014001083B1 BR112014001083B1 (pt) | 2022-02-01 |
BR112014001083B8 true BR112014001083B8 (pt) | 2022-06-14 |
Family
ID=46001349
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112014001083A BR112014001083B8 (pt) | 2011-09-19 | 2012-01-05 | Composto, processo para a preparação de um composto, composição farmacêutica, uso da composiçâo farmacêutica e uso do composto |
Country Status (26)
Country | Link |
---|---|
US (2) | US9079894B2 (pt) |
EP (1) | EP2758394B1 (pt) |
JP (1) | JP5714729B2 (pt) |
KR (1) | KR101551481B1 (pt) |
CN (1) | CN103380131B (pt) |
AP (1) | AP3307A (pt) |
AU (1) | AU2012311057B2 (pt) |
BR (1) | BR112014001083B8 (pt) |
CA (1) | CA2823548C (pt) |
CY (1) | CY1116173T1 (pt) |
DK (1) | DK2758394T3 (pt) |
EA (1) | EA022374B1 (pt) |
ES (1) | ES2531885T3 (pt) |
HK (1) | HK1187340A1 (pt) |
HR (1) | HRP20150229T1 (pt) |
IL (1) | IL231305A0 (pt) |
ME (1) | ME02107B (pt) |
MX (1) | MX337721B (pt) |
PL (1) | PL2758394T3 (pt) |
PT (1) | PT2758394E (pt) |
RS (1) | RS53940B1 (pt) |
SG (1) | SG2014003560A (pt) |
SI (1) | SI2758394T1 (pt) |
SM (1) | SMT201500087B (pt) |
WO (1) | WO2013042135A1 (pt) |
ZA (1) | ZA201309100B (pt) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2833507A1 (en) * | 2011-06-07 | 2012-12-13 | Dainippon Sumitomo Pharma Co., Ltd. | Indazole- and pyrrolopyridine-derivative and pharmaceutical use thereof |
JP2016523813A (ja) * | 2013-04-05 | 2016-08-12 | エービーシー バイオサイエンス エーエス | 医学的使用、特に酸化ストレスまたは炎症に関連する疾患の治療、および臓器の保存または洗浄のための、バレッチンおよびその誘導体 |
NZ720879A (en) * | 2013-12-16 | 2017-05-26 | Suven Life Sciences Ltd | Indazole compounds as 5-ht4 receptor agonists |
HUE052083T2 (hu) * | 2014-08-16 | 2021-04-28 | Suven Life Sciences Ltd | Eljárás 1-izopropil-3-{5-[1-(3-metoxi-propil)-piperidin-4-il]-[1,3,4]oxadiazol-2-il}-1H-indazol-oxalát nagyüzemi termelésére |
NZ734400A (en) * | 2015-02-13 | 2018-03-23 | Suven Life Sciences Ltd | Amide compounds as 5-ht4 receptor agonists |
CN107540568A (zh) * | 2017-08-25 | 2018-01-05 | 许昌恒生制药有限公司 | 一种乙氧酰胺苯甲酯的制备方法 |
WO2020079630A1 (en) * | 2018-10-18 | 2020-04-23 | Suven Life Sciences Limited | New uses of a 5-ht4 receptor agonist |
EP3976192A1 (en) | 2019-05-31 | 2022-04-06 | Ikena Oncology, Inc. | Tead inhibitors and uses thereof |
CN110746450A (zh) * | 2019-09-17 | 2020-02-04 | 济南康和医药科技有限公司 | 一种贝前列素钠关键中间体的合成方法 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06509574A (ja) * | 1991-08-03 | 1994-10-27 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | 5−ht↓4レセプターアンタゴニスト |
TW360653B (en) * | 1995-03-01 | 1999-06-11 | Janssen Pharmaceutica Nv | A oxadiazole compound having colon motility stimulating properties, its preparation process and its pharmaceutical composition |
TR199800827T2 (xx) * | 1995-11-09 | 1999-02-22 | Synthelabo | 5-HT4, H3 resept�r ligandlar� olarak 5-fenil-3-(piperidin-4-il)-1,3,4-oksadiyazol-2(3H)-on t�revleri. |
GB0115862D0 (en) * | 2001-06-28 | 2001-08-22 | Smithkline Beecham Plc | Compounds |
DK1689742T3 (da) | 2003-11-24 | 2010-05-17 | Pfizer | Quinoloncarboxylsyreforbindelser med 5-HT-receptor-agonistisk aktivitet |
EP1856110B1 (en) * | 2005-02-22 | 2011-06-22 | Pfizer Inc. | Oxyindole derivatives as 5ht4 receptor agonists |
CA2598516C (en) | 2005-02-25 | 2010-05-11 | Pfizer Inc. | Benzisoxazole derivatives |
ATE449092T1 (de) | 2005-07-22 | 2009-12-15 | Pfizer | Indazolcarbonsäureamidderivate als agonisten des 5ht4-rezeptors |
KR101121240B1 (ko) * | 2005-12-23 | 2012-06-12 | 에프. 호프만-라 로슈 아게 | 아릴-아이속사졸-4-일-옥사다이아졸 유도체 |
US20080167286A1 (en) * | 2006-12-12 | 2008-07-10 | Abbott Laboratories | Pharmaceutical compositions and their methods of use |
US20080255203A1 (en) * | 2007-04-12 | 2008-10-16 | Abbott Laboratories | Heterocyclic compounds and their methods of use |
ES2542551T3 (es) * | 2009-03-09 | 2015-08-06 | Glaxo Group Limited | 4-Oxadiazol-2-il-indazoles como inhibidores de PI3 cinasas |
-
2012
- 2012-01-05 CN CN201280009072.1A patent/CN103380131B/zh active Active
- 2012-01-05 ME MEP-2015-47A patent/ME02107B/me unknown
- 2012-01-05 US US13/982,486 patent/US9079894B2/en active Active
- 2012-01-05 DK DK12716662.7T patent/DK2758394T3/en active
- 2012-01-05 MX MX2013014577A patent/MX337721B/es active IP Right Grant
- 2012-01-05 AU AU2012311057A patent/AU2012311057B2/en active Active
- 2012-01-05 JP JP2013554062A patent/JP5714729B2/ja active Active
- 2012-01-05 AP AP2013007301A patent/AP3307A/xx active
- 2012-01-05 KR KR1020137020582A patent/KR101551481B1/ko active IP Right Grant
- 2012-01-05 RS RS20150234A patent/RS53940B1/en unknown
- 2012-01-05 EP EP12716662.7A patent/EP2758394B1/en active Active
- 2012-01-05 BR BR112014001083A patent/BR112014001083B8/pt not_active IP Right Cessation
- 2012-01-05 CA CA2823548A patent/CA2823548C/en active Active
- 2012-01-05 SI SI201230163T patent/SI2758394T1/sl unknown
- 2012-01-05 PL PL12716662T patent/PL2758394T3/pl unknown
- 2012-01-05 PT PT127166627T patent/PT2758394E/pt unknown
- 2012-01-05 EA EA201391056A patent/EA022374B1/ru unknown
- 2012-01-05 SG SG2014003560A patent/SG2014003560A/en unknown
- 2012-01-05 ES ES12716662.7T patent/ES2531885T3/es active Active
- 2012-01-05 WO PCT/IN2012/000011 patent/WO2013042135A1/en active Application Filing
-
2013
- 2013-12-04 ZA ZA2013/09100A patent/ZA201309100B/en unknown
-
2014
- 2014-01-10 HK HK14100305.4A patent/HK1187340A1/zh unknown
- 2014-03-04 IL IL231305A patent/IL231305A0/en active IP Right Grant
-
2015
- 2015-02-26 HR HRP20150229AT patent/HRP20150229T1/hr unknown
- 2015-03-30 CY CY20151100308T patent/CY1116173T1/el unknown
- 2015-04-09 SM SM201500087T patent/SMT201500087B/xx unknown
- 2015-06-10 US US14/735,237 patent/US9636335B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112014001083B8 (pt) | Composto, processo para a preparação de um composto, composição farmacêutica, uso da composiçâo farmacêutica e uso do composto | |
BR112015014222A2 (pt) | composto, composição farmacêutica, uso de um composto, método para o tratamento de anemia e composição farmacêutica | |
BR112016016844A2 (pt) | Compostos heterocíclicos | |
BR112015012425A2 (pt) | composto, composição farmacêutica, método e medicamento para o tratamento de doenças medicadas pela proteína parp-1 e uso do composto | |
DOP2014000133A (es) | Triazolopiridinas sustituidas | |
UY32174A (es) | Nuevos heterociclos sustituidos, composiciones farmaceuticas conteniendolos, procedimientos de preparacion y aplicaciones | |
BR112016006651A8 (pt) | derivados de quinolizina substituídos, composição farmacêutica que os compreede e uso dos mesmos. | |
CO6640270A2 (es) | Morfolinopirimidad y su uso en terapia | |
BR112013023517A2 (pt) | "inibidores de produção de leucotrieno, seus usos, e composição farmacêutica" | |
BR112012017382A2 (pt) | compostos inibidores de viroses flaviviridae, uso dos mesmos e composição farmacêutica | |
BR112014018959A8 (pt) | Compostos, composições farmacêuticas, utilizações de um composto e métodos para o tratamento do câncer | |
EA201600366A1 (ru) | Производные бензимидазол-пролина | |
BR112013011580A2 (pt) | derivados de ácido bisfenil pentanoico substituído por amino como inibidores de nep | |
ECSP13013011A (es) | Triazolopiridinas | |
BR112013004662B8 (pt) | Composto, composição farmacêutica, usos de um composto, e método para preparar uma composição farmacêutica | |
BRPI0718436B8 (pt) | compostos antagonistas do receptor b1 da bradicinina derivados de fenilsulfamoilbenzamida, processo para preparar os mesmos, uso dos mesmos e composição farmacêutica | |
BR112015008037A2 (pt) | compostos, processo para a preparação de um composto, composição farmacêutica, utilização do composto, método para o tratamento do câncer e invenção | |
BR112015008717A2 (pt) | composto, composição farmacêutica, método de tratar diabetes do tipo ii, uso do composto de fórmula (i), medicação para o tratamento de diabetes do tipo ii | |
BR112014029439A2 (pt) | derivados de ácido salicílico, sal farmaceuticamente aceitável dos mesmos, composição dos mesmos e método de uso dos mesmos | |
BR112013019160A2 (pt) | novos compostos, composição farmacêutica, uso, processos e métodos | |
EA201990388A1 (ru) | Пиперидиновые модуляторы рецепторов cxcr7 | |
BR112013017362A2 (pt) | composto de fórmula (i), processo para preparar um composto de fórmula (i), composição farmacêutica e compostos, métodos e usos inovadores | |
BR112017026272A2 (pt) | ?composto, composição farmacêutica, método para o tratamento de uma desordem relacionada a receptor m1 muscarínico e uso do composto? | |
EA201400064A1 (ru) | Офтальмологическая фармацевтическая композиция для местного применения, которая содержит регорафениб | |
EA201490573A1 (ru) | Соединение бензотиазолона |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
B08H | Application fees: decision cancelled [chapter 8.8 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 05/01/2012, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO. |
|
B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 4A ANUIDADE. |
|
B21H | Decision of lapse of a patent or of a certificate of addition of invention cancelled [chapter 21.8 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 21.6 NA RPI NO 2679 DE 10/05/2022 POR TER SIDO INDEVIDA. |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: REF. RPI 2665 DE 01/02/2022 QUANTO AO ENDERECO. |